scholarly journals Mast Cells Positive to Tryptase and c-Kit Receptor Expressing Cells Correlates with Angiogenesis in Gastric Cancer Patients Surgically Treated

2013 ◽  
Vol 2013 ◽  
pp. 1-5 ◽  
Author(s):  
Michele Ammendola ◽  
Rosario Sacco ◽  
Giuseppe Sammarco ◽  
Giuseppe Donato ◽  
Valeria Zuccalà ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Mast Cells ◽  
Cancer Patients ◽  
Tumour Tissue ◽  
7Th Edition ◽  
Complex Process ◽  
Kit Receptor ◽  
The Mean ◽  
Gastric Cancer Patients ◽  
Tryptase Inhibitors

Background. Angiogenesis is a complex process involved in both growth and progression of several human and animal tumours. Tryptase is a serin protease stored in mast cells granules, which plays a role in tumour angiogenesis. Mast cells (MCs) can release tryptase following c-Kit receptor (c-KitR) activation.Method. In a series of 25 gastric cancer patients with stage T3N2-3M0(by AJCC for Gastric Cancer 7th Edition), immunohistochemistry and image analysis methods were employed to evaluate in the tumour tissue the correlation between the number of mast cells positive to tryptase (MCPT), c-KitR expressing cells (c-KitR-EC), and microvascular density (MVD).Results. Data demonstrated a positive correlation between MCPT, c-KitR-EC, and MVD to each other. In tumour tissue the mean number of MCPT was 15, the mean number of c-KitR-EC was 20, and the mean number of MVD was 20. The Pearson test correlating MCPT and MVD, c-KitR-EC and MVD was significantly (r=0.64,P=0.001;r=0.66,P=0.041, resp.).Conclusion. In this pilot study, we suggest that MCPT and c-KitR-EC play a role in gastric cancer angiogenesis, so we think that several c-KitR or tryptase inhibitors such as gabexate mesilate and nafamostat mesilate might be evaluated in clinical trials as a new antiangiogenetic approach.

CDK5RAP3 as a Novel Biomarker Signature Predicting Survival and Adjuvant Chemotherapeutic benefit in Gastric Cancer

2020 ◽  
Author(s):  
Jia-Bin Wang ◽  
You-Xin Gao ◽  
Ning-Zi Lian ◽  
Yu-Bin Ma ◽  
Ping Li ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Adjuvant Chemotherapy ◽  
Cancer Patients ◽  
Cox Model ◽  
External Validation ◽  
Tumour Tissue ◽  
Tissue Samples ◽  
Significant Difference ◽  
Validation Set ◽  
Gastric Cancer Patients

Abstract Background: We previously demonstrated that CDK5RAP3 acts as a tumour suppressor in gastric cancer through negative regulation of the Wnt/β-catenin signalling pathway, but its function in chemotherapeutic responsiveness of gastric cancer has not been investigated. In this study, we aimed to examine the clinical significance of CDK5RAP3 to predict chemotherapeutic responsiveness in gastric cancer.Methods: A collection of 188 pairs of tumour tissue microarray specimens from Fujian Medical University were employed for the discovery set, and 310 tumour tissue samples of gastric cancer patients were employed for the internal validation set. Eight-five tumour tissue samples from Qinghai University Hospital were used as the external validation set 1. Transcriptomic and clinical data of 299 gastric cancer patients from TCGA were used as the external validation set 2. CDK5RAP3 expression, microsatellite instability (MSI) status, and tumour-infiltrating lymphocytes (TIL) were examined with immunohistochemistry. Clinical outcomes of patients were compared with Kaplan-Meier curves and the Cox model.Results: In a multi-centre evaluation, increased CDK5RAP3 indication of better prognosis depends mainly on MSI-L/MSS status or TILhigh. High CDK5RAP3 expression predicts sensitive therapeutic responsiveness to postoperative adjuvant chemotherapy in gastric cancer. In a stratification analysis based on CDK5RAP3 combined with TIL or MSI status, patients with CKD5RAP3low TILlow showed no significant difference in prognosis after receiving chemotherapy, whereas patients with CKD5RAP3low TILhigh, CKD5RAP3high TILlow, and CKD5RAP3high TILhigh had better responsiveness to chemotherapy. In addition, patients with CKD5RAP3high MSI-L/MSS status benefitted the most from adjuvant chemotherapy among all patients evaluated. Conclusions: CKD5RAP3 can be used as an effective marker to evaluate individualized chemotherapy regimens in gastric cancer patients dependent on their TIL and MSI status.

Clinical features, treatments and survival of HER2 positive gastric cancer with elevated alpha-fetoprotein: An analysis of 16 cases.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e16000-e16000
Author(s):  
Shaohua Ge ◽  
Yi Ba ◽  
Ting Deng ◽  
Yuchong Yang ◽  
Tao Ning ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Cancer Patients ◽  
Immune Checkpoint ◽  
Clinical Characteristics ◽  
Immune Checkpoint Inhibitors ◽  
Checkpoint Inhibitors ◽  
Elevated Serum ◽  
Her2 Positive ◽  
The Mean ◽  
Gastric Cancer Patients

e16000 Background: Gastric cancer with elevated alpha-fetoprotein (AFP) is a special type of gastric cancer with elevated serum AFP. It is often misdiagnosed as primary hepatic cancer due to abnormal AFP and liver metastasis. The AFP level is related to the prognosis of these patients in whom there is prone to high HER2 positive rate. Therefore, anti-HER2 treatment is optional, as well as the emerging immunotherapy with immune checkpoint inhibitors. Methods: Gastric cancer patients with HER2 and serum AFP examination were collected in our hospital from May 2017 till now. Serum AFP level over 7 ng/ml was defined as elevated AFP. The clinical characteristics, treatments and survival of the patients with HER2 positive and elevated AFP were picked and analyzed. Results: Among 135 gastric cancer patients with elevated AFP, 16 (11.9%) were HER-2 positive (12 with HER2 3+, 3 with HER2 2+/FISH+ and 1 with HER2 gene amplification in NGS). The mean serum AFP is 201.4± 476.7ng/ml (range: 7.74 -1335). There were 9 males and 7 females. The mean age was 55 years (range: 38-90). The tumors were located in stomach cardia and fundus in 5 cases, body in 5 cases, antrum in 4 cases, body and antrum in 1 case and whole stomach in 1 case. There were 2 patients in stage III and 14 patients in stage IV with metastasis to lymph node metastasis in 15, liver in 9, abdominal cavity in 3 and peritoneum in 3. As for the treatments, three patients underwent surgery, one of whom with exploratory laparotomy (no antitumor treatment after surgery, died from infection). In 13 advanced patients, 12 patients received systemic antitumor therapies (8 with chemotherapy+Trastuzumab+ immunotherapy, 2 with chemotherapy+Trastuzumab, 1 with chemotherapy+ immunotherapy and 1 with chemotherapy). The chemotherapy regimens were XELOX in 5 cases, SOX in 4 cases and FLOT in 2 cases. The response rate was 50% (6 in 12 patients) and the disease control rate was 100%. The median PFS was 7.5 months in first line therapy with six patients without progression disease yet. The longest PFS with PR lasted for 16.5 months with chemotherapy, trastuzumab and immune checkpoint inhibitor. Conclusions: Gastric cancer with HER2 positive and elevated serum AFP is a disease with special clinical characteristics. Patients with advanced diseases can be treated with chemotherapy, trastuzumab +/- immune checkpoint inhibitors. This combination is expected to become a new regimen to improve survival of such special patients.

scholarly journals Infiltrating Mast Cells Correlate with Angiogenesis in Bone Metastases from Gastric Cancer Patients

2015 ◽  
Vol 16 (2) ◽  
pp. 3237-3250 ◽  
Author(s):  
Michele Ammendola ◽  
Ilaria Marech ◽  
Giuseppe Sammarco ◽  
Valeria Zuccalà ◽  
Maria Luposella ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Mast Cells ◽  
Bone Metastases ◽  
Cancer Patients ◽  
Gastric Cancer Patients

scholarly journals Tumor-Associated Macrophages and Mast Cells Positive to Tryptase Are Correlated with Angiogenesis in Surgically-Treated Gastric Cancer Patients

2018 ◽  
Vol 19 (4) ◽  
pp. 1176 ◽  
Author(s):  
Giuseppe Sammarco ◽  
Cosmo Damiano Gadaleta ◽  
Valeria Zuccalà ◽  
Emre Albayrak ◽  
Rosa Patruno ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Mast Cells ◽  
Cancer Patients ◽  
Tumor Associated Macrophages ◽  
Gastric Cancer Patients

Comparison of the 6th and 7th editions of the UICC TNM staging system for gastric cancer: Results of a Chinese single-institution study of 1,503 patients.

2011 ◽  
Vol 29 (4_suppl) ◽  
pp. 117-117
Author(s):  
W. Wang
Keyword(s):  
Gastric Cancer ◽  
Cancer Patients ◽  
Likelihood Ratio ◽  
Linear Trend ◽  
Tnm Classification ◽  
Stage Iv ◽  
Tnm Staging ◽  
7Th Edition ◽  
Staging Systems ◽  
Gastric Cancer Patients

117 Background: To evaluate the prognostic efficacy of the 7th edition TNM classification compared to the 6th edition in gastric cancer patients. Methods: A total of 1,503 gastric cancer patients undergoing surgical resection were staged using the 6th and 7th edition staging systems. Homogeneity, discriminatory ability, and monotonicity of gradients of the two systems were compared using linear trend X2, likelihood ratio X2 statistics, and Akaike information criterion (AIC) calculations. Results: Significant differences in five-year survival rates were observed for the “T,” “N,” and “M” subgroups using the 7th edition system, except for stage N2 and N3 patients in the 6th edition system. There were no significant differences in survival between IB and IIA in the 7th edition system. Patients with stage IV disease due to T4/N3 in the 6th edition system who were downstaged to stage III in the 7th edition system had significantly better survival than those who remained at stage IV. The 7th edition system had higher linear trend and likelihood ratio X2 scores, and smaller AIC values compared with those for the 6th edition, which represented the optimum prognostic stratification. Conclusions: Our study suggested that the 7th edition system performs superior to the 6th edition in several aspects. No significant financial relationships to disclose.

scholarly journals CDK5RAP3 as a Novel Biomarker Signature Predicting Survival and Adjuvant Chemotherapeutic Benefit in Gastric Cancer

2020 ◽  
Author(s):  
Jia-Bin Wang ◽  
You-Xin Gao ◽  
Ning-Zi Lian ◽  
Yu-Bin Ma ◽  
Ping Li ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Adjuvant Chemotherapy ◽  
Cancer Patients ◽  
External Validation ◽  
University Hospital ◽  
Tumour Tissue ◽  
Tissue Samples ◽  
Significant Difference ◽  
Validation Set ◽  
Gastric Cancer Patients

Abstract BackgroundWe previously demonstrated that CDK5RAP3 acts as a tumour suppressor in gastric cancer through negative regulation of the Wnt/β-catenin signalling pathway, but its function in chemotherapeutic responsiveness of gastric cancer has not been investigated. MethodA collection of 188 pairs of tumour tissue microarray specimens from Fujian Medical University were employed for the discovery set, and 310 tumour tissue samples of gastric cancer patients were employed for the internal validation set. Eight-five tumour tissue samples from Qinghai University Hospital were used as the external validation set 1. Transcriptomic and clinical data of 299 gastric cancer patients from TCGA were used as the external validation set 2. CDK5RAP3 expression, microsatellite instability (MSI) status, and tumour-infiltrating lymphocytes (TIL) were examined with immunohistochemistry. Clinical outcomes of patients were compared with Kaplan-Meier curves and the Cox model.ResultsIn a multi-centre evaluation, increased CDK5RAP3 indication of better prognosis depends mainly on MSI-L/MSS status or TILhigh. High CDK5RAP3 expression predicts sensitive therapeutic responsiveness to postoperative adjuvant chemotherapy in gastric cancer. In a stratification analysis based on CDK5RAP3 combined with TIL or MSI status, patients with CKD5RAP3low TILlow showed no significant difference in prognosis after receiving chemotherapy, whereas patients with CKD5RAP3low TILhigh, CKD5RAP3high TILlow, and CKD5RAP3high TILhigh had better responsiveness to chemotherapy. In addition, patients with CKD5RAP3high MSI-L/MSS status benefitted the most from adjuvant chemotherapy among all patients evaluated. ConclusionsCKD5RAP3 can be used as an effective marker to evaluate individualized chemotherapy regimens in gastric cancer patients dependent on their TIL and MSI status.

scholarly journals Intratumor IL-17-Positive Mast Cells Are the Major Source of the IL-17 That Is Predictive of Survival in Gastric Cancer Patients

PLoS ONE ◽  
2014 ◽  
Vol 9 (9) ◽  
pp. e106834 ◽  
Author(s):  
Xiaosun Liu ◽  
Hailong Jin ◽  
Geer Zhang ◽  
Xianke Lin ◽  
Chao Chen ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Mast Cells ◽  
Cancer Patients ◽  
Gastric Cancer Patients

scholarly journals AN ANALYTICAL STUDY TO ASSESS AND COMPARE OUTCOME OF CLIPPING VERSUS SUTURE LIGATION OF THE CYSTIC DUCT IN LAPAROSCOPIC CHOLECYSTECTOMY

2021 ◽  
Vol 5 (8) ◽  
Author(s):  
Lakhami Chand Sinsinwar ◽  
Rajvala Choudhary ◽  
Sanjeev Singh Choudhary ◽  
Jeevan Kankaria
Keyword(s):  
Gastric Cancer ◽  
Cancer Patients ◽  
Total Gastrectomy ◽  
Laparoscopic Total Gastrectomy ◽  
Oral Feeding ◽  
Feeding Time ◽  
Early Oral Feeding ◽  
The Mean ◽  
Gastric Cancer Patients

Background: The early oral feeding after the laparoscopic total gastrectomy contributes to the enhanced treatment efficiency and improved quality of life of gastric cancer patients. To evaluate the efficiency of early oral feeding after laparoscopic total gastrectomy in gastric cancer patients at the Nghe An General Friendship Hospital. Methods: A retrospective observational study, performed in patients who underwent laparoscopic total gastrectomy from 2014 to 2020. Results: 126 patients were recruited. The mean age was 60.6 ± 11.1 years. The male/female ratio was 2.8/1. 15.9% of patients had the tumor at the one-third upper stomach, 81.7% at the middle of the stomach. 70.6% of patients contracted adenocarcinoma and ductal carcinoma, 24.6% of patients had ring cell carcinoma. The percent of tumor at stages I, II, III were respectively 19.0%, 49.2%, 31.7%. There were 71.4% of cases underwent laparoscopic total gastrectomy and were made the anastomosis by linear staplers. No case presented complications relating to the anastomosis after the surgery. The mean oral feeding time was 4.4 ± 1.9 (2 – 8 days), 27.8% of cases started at the second postoperative date, 8.7% of cases at the third postoperative date, 29.4% of cases from the fourth and fifth date, and 34.1% of cases started from the sixth date and further. The later the oral feeding time was, the slower recovery of the peristalsis was and vice versa (p < 0.05). There was no difference between the feeding time and the complications (p > 0.05). The more early the feeding time was, the shorter duration of antibiotic therapy observed and vice versa (p < 0.05). The more early the feeding time was, the short duration of hospital stay was and vice versa (p < 0.05). Conclusions: The early oral feeding after laparoscopic total gastrectomy was safe and contributed to improving the efficiency of the treatment, the quality of life in gastric cancer patients. Keywords: Early oral feeding, gastric cancer.

Infiltration Patterns of Immune Cells in Gastric Cancer and Their Clinical Correlation with Prognosis

2020 ◽  
Author(s):  
XiaoLi Wu ◽  
Hongbo Ma ◽  
YanYan Li
Keyword(s):  
Gastric Cancer ◽  
T Cells ◽  
Mast Cells ◽  
Nk Cells ◽  
Cancer Patients ◽  
Cd8 T Cells ◽  
Immune Cells ◽  
Immune Cell ◽  
M1 Macrophages ◽  
Gastric Cancer Patients

Abstract Abstract: Objective Gastric cancer is a malignant tumour that severely affects the health of patients. This study analyses the correlation between gastric cancer-infiltrating immune cell patterns and clinical prognosis and provides a scientific basis for the development of comprehensive tumour prevention and treatment strategies. Method Transcripts and related clinical data from 9-2019 for gastric cancer were downloaded from the TCGA database. The proportions of 22 kinds of immune cells were calculated by CIBERSORT software, and the correlation of each immune cell component ratio with tumour grade, clinical stage and overall survival (OS) was evaluated. Results A total of 413 gene transcript data sets were obtained from the TCGA database, including 381 for gastric cancer and 32 for normal tissues. The expression of various macrophages in tumour tissues was abundant. The immune cell composition, which included resting dendritic cells (p=0.02), M1 macrophages (p=0.031), resting mast cells (p=0.02), CD8 T cells (p=2.445e-04), M0 macrophages (p=6.353e-04), activated mast cells (p=0.006), neutrophils (p=0.003), resting NK cells (p=0.014), and gamma delta T cells (p=0.033), is related to the pathological grade. As the tumour stage of gastric cancer patients progresses, the proportion of some immune cells, including eosinophils (p=0.013), activated mast cells (p=0.042), neutrophils (p=0.007), and resting NK cells (p=0.036) gradually increases, while the proportion of other immune cells, for example, CD8 T cells (p=0.018), Tregs (p=0.039), M1 macrophages (p=0.018), and activated NK cells (p=0.042) gradually decreases. Higher expression of CD8 T cells suggests a better prognosis. Conclusion The composition of tumour-infiltrating immune cells differed greatly in different pathological grades and stages of gastric cancer. CD8 T cells can be used as a prognostic factor for gastric cancer patients.

Sign in / Sign up

Export Citation Format

Share Document